Technology ID
TAB-4829

Vaccine for Cats to Block Toxoplasma Gondii Oocyst Shedding and Transmission. Description of Technology

E-Numbers
E-118-2023-0
Lead Inventor
Grigg, Michael (National Institute of Allergy and Infectious Diseases)
Co-Inventors
Sardinha da Silva, Aline (National Institute of Allergy and Infectious Diseases (NIAID/NIH))
Pszenny, Viviana (National Institute of Allergy and Infectious Diseases (NIAID/NIH))
Dubey, J. P. (US Department of Agriculture (USDA))
Julius, Lukes (University of South Bohemia in Ceské Budejovice)
Development Status
Pre-Clinical

­       Toxoplasma gondii is the zoonotic causative agent of toxoplasmosis, a disease of significant concern for pregnant persons and livestock. A member of the phylum Apicomplexa, Toxoplasma gondii can infect almost any cell type found in mammals and birds. There are multiple transmission pathways, including consumption of undercooked meat from infected animals, consumption of unwashed plants, contaminated water supplies, blood transfers, and congenital transfer. Felines are considered the definitive host of Toxoplasma gondii. Direct or indirect transmission can occur via contact with the stool of infected felines.

Potential Commercial Applications:     

  • Live vaccine for felines against Toxoplasma gondii infection
  • Reduction in environmental Toxoplasma gondii oocysts

Competitive Advantages: 

  • 100% blocked Toxoplasma gondii oocyst shedding in felines
  • Detectable seroconversion protective against future Toxoplasma gondii infection
  • Scalable production strain with predictable inactivation of IFT88 or SRS15B gene
  • Materials available for development or licensing

      Researchers at the National Institute of Allergy and Infectious Diseases (NIAID), the U.S. Department of Agriculture (USDA), and the University of South Bohemia (České Budějovice, Czechia) have demonstrated that T. gondii strains lacking expression of either the intracellular transport protein IFT88 or the CYS-6-type surface antigen SRS15B prevent the formation of oocysts and have potential for broad immunity to T. gondii. The inventors propose that mass inoculation of felines, specifically wild or feral felines, with a live vaccine developed from these strains could result in a significant reduction in oocyst production and environment contamination, reducing further infection in a geographical area. It is also proposed that loss of IFT88 or SRS15B homologs in other Apicomplexa parasites, like Neospora, Sarcocystis, or Cryptosporidium could have a similar impact.

      This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.

Commercial Applications
  • Live vaccine for felines against Toxoplasma gondii infection
  • Reduction in environmental Toxoplasma gondii oocysts
Competitive Advantages
  • 100% blocked Toxoplasma gondii oocyst shedding in felines
  • Detectable seroconversion protective against future Toxoplasma gondii infection
  • Scalable production strain with predictable inactivation of IFT88 or SRS15B gene
  • Materials available for development or licensing
Licensing Contact:
Mattes, Theodoric
theodoric.mattes@nih.gov
Phone: 301-496-2644